StreetAlpha.app
Home › Stocks › NBIX

Neurocrine Biosciences Inc (NBIX)

$150.57
▼ −3.84%
LAST CLOSE · NOV 20

Neurocrine Biosciences develops and sells medicines for neurological, psychiatric and endocrine disorders, based in San Diego. It last closed at $150.57 on Nov 20, down 3.84% on the day. The next earnings report for NBIX is expected around Wed, Feb 10, 2027, after the close. For the quarter ended Sep 2026, NBIX reported EPS of $1.96 on revenue of $1.12B, with revenue up 41.2% from a year ago. Over its last 8 reports the stock moved an average of 10.3% the session after earnings. Over the last 12 months NBIX insiders bought $0 of stock on the open market and sold $79.9M, according to SEC Form 4 filings.

AI Auto Pilots
Is NBIX in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold NBIX.

Key Stats

Last 12 months
Results
Revenue
$3.7B
+38.0% vs a year ago
Net income
$702.5M
+64.1% vs a year ago
EPS (diluted)
$6.74
+60.9% vs a year ago
Free cash flow
$1.0B
28.1% margin
Valuation
Market cap
$15.2B
101.2M shares
P/E
22.3
Price over 12 month EPS
Price to sales
4.1
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$641.5M
At Sep 30
Shareholder equity
$3.9B
Buybacks
$158.1M
Last 12 months
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $1.1B$1.1BFY2021FY2022: $1.5B$1.5BFY2022FY2023: $1.9B$1.9BFY2023FY2024: $2.4B$2.4BFY2024FY2025: $2.9B$2.9BFY2025

From NBIX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 2). Last 12 months adds up the four latest quarters.

Next report
Feb 10
Estimated date · After the close
Reported EPS
$1.96
Quarter ended Sep 2026
Year ago EPS
$2.04
−3.9% on a GAAP basis
Revenue
$1.12B
+41.2% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: $1.00Dec '24Mar 2025: $0.08Mar '25Jun 2025: $1.06Jun '25Sep 2025: $2.04Sep '25Dec 2025: $1.48Dec '25Mar 2026: $1.91Mar '26Jun 2026: $1.39Jun '26Sep 2026: $1.96Sep '26Latest $1.96
Revenue by quarter
Dec 2024: $627.7MDec '24Mar 2025: $572.6MMar '25Jun 2025: $687.5MJun '25Sep 2025: $794.9MSep '25Dec 2025: $805.5MDec '25Mar 2026: $814.5MMar '26Jun 2026: $959.0MJun '26Sep 2026: $1.12BSep '26Latest $1.12B
How NBIX moved after its last 8 reports
Average move the session after a report ±10.3%
Nov 2, 2026After the close+13.4%
Jul 30, 2026After the close−10.1%
May 5, 2026After the close+8.9%
Feb 11, 2026After the close−10.4%
Oct 28, 2025After the close−6.3%
Jul 30, 2025After the close−6.2%
May 5, 2025After the close+8.4%
Feb 6, 2025After the close−18.5%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on NBIXStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on NBIX
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on NBIX

Technical Analysis

NBIX · as of the Nov 20 close · updated each morning
Moving sideways

The stock sits between its 20 and 50 day averages. It is sitting right on its 200 day average, a level many traders watch. Momentum is weak (RSI 43). The nearest support is the 200 day average at $149.44, and the nearest resistance the Pivot at $153.02.

Short trendNeutral
Long trendNeutral
MomentumWeak
StretchNormal
VolatilityHigh, 3.7%/day
Key levels
$186.1252 week high+23.6%
$159.0520 day average+5.6%
$156.93100 day average+4.2%
$156.56Swing high (Aug 19)+4.0%
$155.80Pivot R1+3.5%
$153.02Pivot+1.6%
$150.57Last close
$149.44200 day average−0.8%
$149.0350 day average−1.0%
$148.78Swing low (Aug 14)−1.2%
$147.79Pivot S1−1.8%
$122.1452 week low−18.9%
Indicators
RSI (14)42.95Middle of its rangeNeutral
MACD3.59Below its signal lineBearish
Stochastic35.0Middle of its rangeNeutral
ADX (14)29.5Trending down
Williams %R-98.6Oversold below −80, overbought above −20Oversold
CCI (20)-46.5Oversold below −100, overbought above 100Neutral
Rate of change−8.5%Change over 10 sessionsBearish
ATR (14)$5.63Typical daily range, 3.7% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Below
MA 200Above
What happened before, for NBIX

What happened before

See how NBIX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow NBIX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How NBIX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2005.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for NBIXHow many large options trades hit NBIX, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

NBIX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●406 buying vs 364 selling
  • ●Held by funds +0.3 pts
  • ▼Funds holding -9
  • ▲Superinvestors: 3 added, 1 cut
  • ▼Put/call 0.03 to 0.05
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding773782−1.2%
In funds' top 1079−22.2%
Held by funds100.2%99.9%+0.3 pts
New / increased102 / 304145 / 320−12.7%
Reduced / sold out257 / 107224 / 65+26.0%
Put/call ratio0.050.03+31.9%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See NBIX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

NBIX Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$79.9M26 sales · 14 insiders
100% of the selling was under pre-arranged trading plans.
2025-12 sold $3.9M2026-01 sold $4.8M2026-05 sold $43.5M2026-06 sold $13.6M2026-07 sold $5.4M2026-09 sold $826K2026-11 sold $4.8MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 17Gary A LyonsDirectorSale plan15,000$164.87$2.5M
Nov 3George J MorrowDirectorSale plan15,000$155.73$2.3M
Sep 14Matt AbernethyCFOSale plan2,311$157.20$363K
Sep 14David W. BoyerChief Corp. Affairs OfficerSale plan826$157.45$130K
Sep 9Eric BenevichChief Commercial OfficerSale plan2,154$154.61$333K
Jul 28Leslie V NorwalkDirectorSale plan1,250$182.01$228K
Every insider buy and sale for NBIX over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See NBIX insider trades →

From SEC Form 4 filings by NBIX's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NBIX is in one of them and how their past NBIX trades turned out.

NBIX in the AI portfolios
Loading…

NBIX News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered NBIX in an article yet. Here's the latest on the wider market.

NBIX in the news

NBIX Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed Aug 13
Who traded NBIX · since 2018
Latest 5 filings
Lisa McClainSell (partial)
$1K – $15KTraded Jun 17, 2025Filed Aug 13, 2025
$1K – $15KTraded Jun 11, 2025Filed Aug 13, 2025
$1K – $15KTraded Dec 21, 2020Filed Jan 11, 2021
Gilbert CisnerosSell (partial)
$1K – $15KTraded Jul 21, 2020Filed Aug 19, 2020
$1K – $15KTraded Dec 13, 2018Filed Jan 4, 2019
PersonTypeAmountTradedFiledDelay
Lisa McClainR · MISell (partial)$1K – $15KJun 17, 2025Aug 13, 202557 d
Lisa McClainR · MIBuy$1K – $15KJun 11, 2025Aug 13, 202563 d
Gilbert CisnerosD · CABuy$1K – $15KDec 21, 2020Jan 11, 202121 d
Gilbert CisnerosD · CASell (partial)$1K – $15KJul 21, 2020Aug 19, 202029 d
Josh GottheimerD · NJSell$1K – $15KDec 13, 2018Jan 4, 201922 d

From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data

About Neurocrine Biosciences

Neurocrine Biosciences is a biopharmaceutical company based in San Diego, California. It discovers, develops and sells medicines for neurological, psychiatric, endocrine and immune disorders. Its main product, INGREZZA, treats tardive dyskinesia and chorea linked to Huntington's disease, and CRENESSITY treats congenital adrenal hyperplasia. In the United States, it sells through specialty pharmacies and distributors, and its sales teams focus on neurology, psychiatry, long-term care and rare diseases.

Headquarters
San Diego, CA
Founded
1992